Clinical experience with netilmicin.
From the results from over 150 clinical trials of netilmicin 3376 completed patient treatment courses have been reviewed to assess its efficacy and safety. Fourteen-hundred and twenty-three patients with 2273 infections caused by 2322 pathogens were evaluable for treatment efficacy. Favourable clinical responses were observed in 90% of the infections treated. Eighty-three per cent of the causative pathogens were eliminated from the infection sites. Netilmicin's safety was evaluated in all patients. Nephrotoxicity considered to be probably netilmicin-related occurred in 1.7% of the patients, and was possibly related in an additional 5.2%. Auditory toxicity was probably netilmicin-related in 1.6% and possibly related in 1.9% of the patients. Vestibular toxicity, probably or possibly drug-related, was observed in 0.62% of the patients. Extensive clinical trials with netilmicin have confirmed its excellent efficacy and safety profile.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009428:Netilmicin / Q000627:therapeutic use*; D000159:Vestibulocochlear Nerve / Q000187:drug effects
D005839:Gentamicins; D009428:Netilmicin